Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027

About this update from Appili Therapeutics Inc Class A

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027Appili adopts a new business strategy that focuses on the biodefence sectorHalifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless otherwise stated."While ATI-1801 remains the Company's principal near-term regulatory and value-creation opportunity, Appili is expanding its portfolio strategy to build a broader biodefence and health-security company, with an increased emphasis on defence-related medical needs," said Dr. Don Cilla, President and CEO of Appili.Revised Business StrategyThe Company was founded to acquire, develop, and commercialize novel therapeutics addressing infectious diseases and biodefense priorities. Our revised strategic focus is driven by the significant unmet medical and public health need for innovative countermeasures against naturally occurring and emerging infectious diseases, antimicrobial resistance, and biological threats, as well as the expanding regulatory, procurement, and non-dilutive funding mechanisms available to support development. These opportunities are increasingly supported by U.S. Government agencies, allied governments, and international organizations seeking resilient biodefense and health security capabilities. TRUQUESTATM (ATI-1801) - Topical Antiparasitic Program with an Aligned Regulatory PathFollowing positive feedback from the U.S. Food and Drug Administration ("FDA") on its scientific bridging strategy, TRUQUESTATM, a topical formulation of paromomycin in development for cutaneous leishmaniasis has a clearly defined registration pathway to support an NDA submission. Appili is actively pursuing non-dilutive funding from global health organizations and government agencies that share the Company's focus on tropical diseases to execute this strategy and complete the remaining development work.Appili's TRUQUESTATM is potentially eligible to receive a Priority Review Voucher ("PRV") upon FDA approval, which is anticipated as early as the fourth quarte...

View stock analysis, news, and events for Appili Therapeutics Inc Class A